BVM Capital
VC Fund
New York, United States
BVM Capital is a VC fund in New York focused on Therapeutics and Biotechnology. BVM Capital LLC is a Southeast-based venture capital firm that invests opportunistically.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries BVM Capital invests in
Stages BVM Capital invests in
Countries BVM Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Therapeutics 2 (100%)
- Biotechnology 2 (100%)
- Biopharma 1 (50%)
- Medical Device 1 (50%)
Stage
- Seed 1 (50%)
- Series A 1 (50%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Ross Barrett
Founder, General Partner
|
Founder, General Partner | Total investments: 8 | Find email | |
Russell Vernon
General Partner
|
General Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Embera NeuroTherapeutics is a development stage pharmaceutical company focused on developing treatments for smoking cessation and other addictions, for which there are a limited range of effective drug therapies or have no approved treatments. Embera is developing a novel addiction treatment (EMB-001) that targets specific and complementary brainfunctions that drive the craving and relapse associated with these disorders, an approach based on breakthrough discoveries of the scientific founder. | $2.3M / Series A / Feb 26, 2015 | ||
| Calosyn Pharma Inc. is developing therapies for osteoarthritis (OA). OA is the leading cause of disability in the US, affecting 27 million people, and worldwide OA affects over 100 million people. Current therapies for OA leave a large portion of the OA patient population with non-ideal options; we aim to help these patients.Their product isbased on a class of drugs known as calcium channel blockers. These drugs have been used safely in humans for many decades in the treatment of heart and vascular diseases. Taking advantage of new knowledge in how these drugs work and in how osteoarthritis results in joint damage and pain, we have reformulated and repurposed these drugs for injection directly into the osteoarthritic joint.Calosyn Pharma is currently enrolling patients in a Phase II proof of efficacy clinical trial in the United States. | $400K / Seed / Jun 30, 2009 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does BVM Capital invest in?
BVM Capital invests primarily in Therapeutics, Biotechnology and Biopharma startups, most often at Seed and Series A stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact BVM Capital?
Public channels for BVM Capital include X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at BVM Capital?
The team at BVM Capital includes Ross Barrett (Founder, General Partner) and Russell Vernon (General Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
